| Overview |
| bs-8511R-Cy7 |
| NLRX1 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NLR family member X1 |
| 111-210/975 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 79671 |
| Q86UT6 |
| Cytoplasm, Cell membrane |
| NOD5; NOD9; NOD26; DLNB26; CLR11.3; NLR family member X1; Caterpiller protein 11.3; Nucleotide-binding oligomerization domain protein 26; Nucleotide-binding oligomerization domain protein 5; Nucleotide-binding oligomerization domain protein 9; NLRX1 |
| Participates in antiviral signaling. Acts as a negative regulator of MAVS-mediated antiviral responses, through the inhibition of the virus-induced RLH (RIG-like helicase)-MAVS interaction (PubMed:18200010). Has no inhibitory function on NF-Kappa-B and type 1 interferon signaling pathways, but enhances NF-Kappa-B and JUN N-terminal kinase dependent signaling through the production of reactive oxygen species (PubMed:18219313). |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz